Clinical Trials Browser

Phase 1/2 × ferric pyrophosphate × 90 days × Clear all

NCT01318317 2026-05-05

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

8 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell